Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Epilepsy, Tonic-Clonic: later-stage trial registry
1 of 3 indexed Epilepsy, Tonic-Clonic trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Epilepsy, Tonic-Clonic: 3 US clinical trials tracked, 1 recruiting.
Epilepsy, Tonic-Clonic is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is LivaNova, running 1 of these trials.
Enrollment posture brief
Registry condition epilepsy-tonic-clonic
OPEN 1 | RECR 33% | LATE 1 | EARLY 0 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Epilepsy, Tonic-Clonic lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Epilepsy, Tonic-Clonic on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Epilepsy, Tonic-Clonic is recruiting below its size-band peers.
1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy
Neuroelectrics Corporation
NCT04770337
Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Primary Generalized Tonic-Clonic Seizures (PGTC) Seizures
GlaxoSmithKline
NCT00104416
Microburst Vagus Nerve Stimulator (VNS) Therapy Feasibility Study
LivaNova
NCT03446664
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Epilepsy, Tonic-Clonic records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Epilepsy, Tonic-Clonic trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Epilepsy, Tonic-Clonic page
3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Epilepsy, Tonic-Clonic trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- LivaNova sponsors the most Epilepsy, Tonic-Clonic trials on record, review their full trial history before evaluating a specific study. See LivaNova's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Epilepsy, Tonic-Clonic condition card totals 3 registered trials; most-linked intervention lamotrigine (LAMICTAL) extended-release; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.